Table 4.
Outcomes of anakinra vs. no anakinra groups before and after propensity score matching
| Before propensity score matching | After propensity score matching | |||||
|---|---|---|---|---|---|---|
| Outcomes | Anakinra (N = 57) |
No Anakinra (N = 52) |
p value | Anakinra (N = 31) |
No Anakinra (N = 31) |
p-value |
| Duration of organ support, median (IQR) | ||||||
| Vasoactive support (hours) | 19.6 (8.9–55.7) | 20.6 (12.5–31.3) | 0.25 | 16.2 (8.3–48.5) | 19.1 (11.7–34.2) | 0.64 |
| Respiratory support (days) | 3.0 (2.0-5.5) | 2.0 (1.0-6.8) | 0.23 | 5 (1–8) | 2 (1–6) | 0.14 |
| Organ support, n (%) | ||||||
| Respiratory support | 39 (68) | 34 (65) | 0.73 | 18 (58) | 24 (77) | 0.1 |
| Vasoactive support | 44 (77) | 24 (46) | 0.0008 | 21 (68) | 22 (71) | 0.78 |
| VIS, day 1, median (IQR) | 10.0 (6.0–15.0) | 7.0 (5.0-10.2) | 0.3 | 7.0 (6.0–13.0) | 6.0 (5.0-9.5) | 0.76 |
| Presence of fever | ||||||
| Fever duration during admission (days), median (IQR) | 1 (1–2) | 2 (1–3) | 0.09 | 2 (1–3) | 1 (1–3) | 0.43 |
| Max temperature (oC), day 2, median (IQR) | 37.3 (36.7–38.3) | 38.2 (36.9–39.1) | 0.01 | 37.9 (37.2–39.1) | 38.2 (36.9–38.9) | 0.84 |
| Fever, day 2, n (%) | 19 (33) | 27 (52) | 0.04 | 15 (48) | 18 (58) | 0.44 |
| Max temperature (oC), day 3, median (IQR) | 37.1 (36.8–37.9) | 37.2 (36.8–38.1) | 0.23 | 37.3 (36.7–38.7) | 37.2 (36.7–37.8) | 0.5 |
| Fever, day 3, n (%) | 12 (21) | 12 (23) | 0.79 | 10 (32) | 6 (19) | 0.24 |
| Fever, day 4, n (%) | 6 (11) | 13 (25) | 0.046 | 5 (16) | 8 (26) | 0.34 |
| Fever, day 5, n (%) | 3 (5) | 10 (19) | 0.024 | 5 (16) | 4 (13) | 0.71 |
| CRP, median (IQR) | ||||||
| CRP, day 2 | 16.5 (13.9–21.0) | 15.2 (10.9–19.9) | 0.21 | 15.7 (13.3–19.9) | 16.4 (11.8–20.3) | 0.72 |
| CRP, day 3 | 11.6 (7.8–17.0) | 10.9 (7.9–16.8) | 0.25 | 11.6 (8.7–18.6) | 11.3 (8.4–16.9) | 0.62 |
| VIS, median (IQR) | ||||||
| VIS, day 2 | 5.0 (4.3-8.0) | 8.5 (4.0–16.0) | 0.33 | 7.0 (6.0–13.0) | 6.0 (5.0-9.5) | 0.76 |
| VIS, day 3 | 4.5 (2.0–7.0) | 8.0 (5.8–10.0) | 0.33 | 5.0 (4.0–8.0) | 5.0 (2.0–11.0) | 0.82 |
| Echo findings | ||||||
| LV dysfunction, n (%) | 24 (42) | 8 (15) | 0.94 | 9 (29) | 9 (29) | 1 |
| LVSF, median (IQR) | 30 (24–33) | 32 (29–35) | 0.01 | 32 (28–35) | 32 (26–34) | 0.28 |
| CAA, n (%) | 5 (9) | 2 (4) | 0.29 | 5 (16) | 0 (0) | 0.05 |
| Length of stay (days), median (IQR) | ||||||
| ICU LOS | 2.5 (1.3–4.3) | 2.0 (1.6–5.9) | 0.54 | 1.8 (1.1–5.5) | 2.11 (1.7–6.2) | 0.18 |
| Hospital LOS | 7.8 (6.7–10.2) | 5.9 (4.4–8.4) | 0.00007 | 8.7 (6.6–11.0) | 6.1 (4.4–9.6) | 0.002 |
| Time from initial steroid dose to discharge | 6.8 (6.0-9.6) | 5.0 (4.0-6.8) | 0.00001 | 8.1 (6.1–9.9) | 5.2 (4.25–7.5) | 0.0008 |